Real World Evidence

In today’s high-cost R&D environment, pharma success depends less on cost-cutting and more on evidence-based portfolio decisions, niche-buster strategies, and real-world data-driven indication expansion to maximize both ROI and patient outcomes.

A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial design, targeted patient selection, and real-world evidence to speed label expansion.

Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.

A new global report finds that clinical research teams are making progress but still lack the skills and tools needed to keep pace with growing trial complexity and emerging technologies.

How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating evidence in broader, more representative patient populations.

As clinical research increasingly relies on RWD to enhance trial design and patient insights, tokenization has emerged as a critical solution for securely linking disparate datasets while protecting patient privacy.

In this video interview, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer Network (NCCN), explores how emerging technologies such as wearable devices, real-world data analysis, and decentralized trial designs can improve the identification and engagement of potential cancer clinical trial participants.

In this video interview, C.K. Wang, MD, chief medical officer, COTA, touches on how he would like to see greater industry collaboration in connecting cancer patients with RWD.

In this video interview, C.K. Wang, MD, chief medical officer, COTA, shares his key takeaways from a recent study he led on data reporting in oncology and highlights how stakeholders should be closely analyzing the accuracy of data they work with.

In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses a recent study he led on the validity of using real-world data for reporting mortality.

The ongoing evolution of real-world evidence from a novel concept to a cornerstone of modern medical research signifies its growing importance and vast potential to improve personalized medicine, overall healthcare outcomes, and eventually democratization of scientific facts by general accessibility.

Webinar Date/Time: Mon, Dec 2, 2024 11:00 AM EST

Webinar Date/Time: Tuesday, December 10th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Webinar Date/Time: Wednesday, November 13th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

A look at the insights and implications surrounding the agency's recommendations on using RWE from electronic health records and medical claims data.

Webinar Date/Time: Thursday, September 12th, 2024 at 11am EDT|8am PDT|4pm BST|5pm CEST

The potential of personal health records to bridge the gap between research and care.

Webinar Date/Time: Thursday, May 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Webinar Date/Time: Tue, Mar 26, 2024 11:00 AM EDT

In an interview with ACT editor Andy Studna at SCOPE, Deyle, VP & GM, Clinical Research, Flatiron Health discusses real-world evidence in clinical trials.

Webinar Date/Time: Wed, Mar 27, 2024 11:00 AM EDT

Study highlights the potential of a comprehensive, multistakeholder-driven data analysis pipeline that addresses individual data sharing, core data set sharing, and federated model sharing.